Skip to content

Adolescent Depression Screening and Treatment in Mozambican Primary Care

Pilot Implementation of Depression Screening and Treatment for Adolescents in Mozambican Primary Care

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05476237
Enrollment
95
Registered
2022-07-27
Start date
2023-04-01
Completion date
2024-09-27
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Behavior, Depression

Keywords

adolescent depression

Brief summary

This is a cluster-randomized pilot trial of depression screening and treatment implementation at four Youth-friendly Health Services (YFHS) in primary care clinics, two in Maputo City and two in Maputo Province. YFHS will be stratified by urbanicity, such that one YFHS in Maputo City and one YFHS in Maputo Province will be randomized to interpersonal psychotherapy (IPT)-A and the other YFHS in each location with be randomized to treatment as usual (TAU).

Detailed description

Mental disorders are the leading cause of disability among adolescents worldwide, but only a very small minority, mostly in high-resource settings, have access to mental health care. The investigators' work is focused on understanding how to increase access to mental health care for adolescents in low-resource settings. In Mozambique, where this work is based, there are just 15 psychiatrists and 180 psychologists to serve its population of 29 million. In collaboration with local stakeholders, including governmental policymakers and primary care providers, the investigators developed a plan to implement care for adolescent depression in primary care settings. The investigators now aim to examine changes in adolescent depression and acceptability of primary care-based mental health services compared to treatment as usual.

Interventions

BEHAVIORALGroup Interpersonal Therapy for Adolescents (IPT-AG)

IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.

BEHAVIORALTreatment as Usual (TAU)

Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).

Sponsors

Columbia University
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Providers: 1. IPT-AG Arm: YFHS staff will be included in the study if they (a) conduct screening for depression and/or group IPT-AG and (b) provide consent to participate in the study. 2. TAU Arm: YFHS staff will be included in the study if they (a) provide referrals for adolescents suspected of having mental illness or seeking mental health services and (b) provide consent to participate in the study. Treatment providers (Psychiatric Technicians and psychologists) will be included in the study if they (a) treat adolescents referred from participating YFHS for depression and (b) provide consent to participate in the study. 2. Patients: In both study arms, adolescents attending one of the four study YFHS will be included in the study if they: 1. are between the ages of 12-19 years; 2. screen positive for depression; 3. provide informed consent (ages 16 -19) or if their guardian provides informed consent and they provide assent (if ages 12-15). 3. Study centers: must be clinics that have YFHS.

Exclusion criteria

In both study arms, adolescents will be excluded if they: 1. are unable to participate in treatment due to acute illness; and/or 2. are unable to communicate sufficiently in Portuguese to answer inclusion questions.

Design outcomes

Primary

MeasureTime frameDescription
IPT-AG Fidelity6 months post-interventionThe Group IPT-AG Fidelity Checklist is a 14-item scale that measures provider fidelity to group interpersonal therapy for adolescents. Providers are scored for superior (1), satisfactory (2), or needs improvement (3) adherence to each item on the checklist, which each represent and essential element of treatment (e.g., gives hope that depression is treatable, links depression to interpersonal problems). The score of the 14-items is averaged to compute the IPT-AG Fidelity rating (1=superior, 2=satisfactory, 3=needs improvement). The total score range is 1 to 14, with a lower score indicating a better outcome. This outcome was only assessed in participants who received the study intervention.
Change in PHQ-A Score From Baseline to 6 Months Post-interventionBaseline, 6 monthsThe Patient Health Questionnaire (PHQ)-A is a 9-item severity measure of depression for adolescents adapted from the PHQ-9. Questions ask how often an adolescent has been bothered by different depression symptoms in the past week, and responses of "not at all," "several days," "more than half the days," and "nearly every day" are given scores of 0 to 3. A total score is calculated by summing the value of all items and ranges from 0 (better outcome) to 27 (worse outcome). The change in PHQ-A score will be reported as a percent change.

Countries

Mozambique

Contacts

PRINCIPAL_INVESTIGATORKathryn Lovero, PhD

Columbia University

Baseline characteristics

Characteristic
Age, Continuous16.1 years
STANDARD_DEVIATION 2.2
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
83 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
Mozambique
12 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 830 / 12
other
Total, other adverse events
20 / 831 / 12
serious
Total, serious adverse events
0 / 830 / 12

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026